• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶组织梭状芽孢杆菌胶原酶对佩罗尼氏病患者阴茎血管及形态学参数的影响。

Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease.

作者信息

Diao Linley, Anaissie James, Nguyen Hoang Minh Tue, Yafi Faysal A, Haney Nora M, DeLay Kenneth J, Peak Taylor C, Sikka Suresh C, Hellstrom Wayne J G

机构信息

Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.

出版信息

Transl Androl Urol. 2017 Oct;6(5):894-898. doi: 10.21037/tau.2017.07.27.

DOI:10.21037/tau.2017.07.27
PMID:29184789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5673819/
Abstract

BACKGROUND

To examine the changes in penile vascular parameters after the administration of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD).

METHODS

We retrospectively reviewed the records for all patients treated with CCH for PD between 04/2014 and 05/2017 who underwent penile duplex Doppler ultrasound (PDDU) after pharmacologically induced erection both before and after four cycles of CCH treatment. The primary outcomes measured were changes in peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) after CCH treatment. Paired -tests, chi-squared tests, and correlation coefficients were performed between functional and vascular parameters before and after four rounds of CCH to determine statistical significance (P<0.05).

RESULTS

A total of 51 patients were included in the study. After four cycles of CCH therapy, there was no statistically significant change in PSV, EDV, RI, or International Index of Erectile Function score when compared to baseline. Similarly, there was no correlation between vascular parameters and change in curvature. There was a statistically significant change in penile curvature (60˚±16.9˚ to 40.8˚±14.9˚, P<0.001) and erect penile circumference (11.6±1.0 to 11.9±1.0 cm, P<0.05) after treatment.

CONCLUSIONS

In spite of a significant change in penile curvature, this change did not correlate with changing penile vascular or morphological parameters. Overall, CCH therapy seems to have a negligible impact on penile vasculature, furthering evidence of its favorable safety profile.

摘要

背景

研究注射溶组织梭状芽孢杆菌胶原酶(CCH)后佩罗尼氏病(PD)患者阴茎血管参数的变化。

方法

我们回顾性分析了2014年4月至2017年5月间接受CCH治疗的所有PD患者的记录,这些患者在CCH治疗的四个周期前后均接受了药物诱导勃起后的阴茎双功能多普勒超声(PDDU)检查。主要测量指标为CCH治疗后收缩期峰值流速(PSV)、舒张末期流速(EDV)和阻力指数(RI)的变化。在四轮CCH治疗前后,对功能和血管参数进行配对检验、卡方检验和相关系数分析,以确定统计学意义(P<0.05)。

结果

共有51例患者纳入研究。与基线相比,CCH治疗四个周期后,PSV、EDV、RI或国际勃起功能指数评分无统计学显著变化。同样,血管参数与曲率变化之间也无相关性。治疗后阴茎曲率(60˚±16.9˚至40.8˚±14.9˚,P<0.001)和勃起阴茎周长(11.6±1.0至11.9±1.0 cm,P<0.05)有统计学显著变化。

结论

尽管阴茎曲率有显著变化,但这种变化与阴茎血管或形态参数的改变无关。总体而言,CCH治疗似乎对阴茎血管系统影响可忽略不计,进一步证明了其良好的安全性。

相似文献

1
Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease.溶组织梭状芽孢杆菌胶原酶对佩罗尼氏病患者阴茎血管及形态学参数的影响。
Transl Androl Urol. 2017 Oct;6(5):894-898. doi: 10.21037/tau.2017.07.27.
2
Predictors of Curvature Improvement in Men With Peyronie's Disease Treated With Intralesional Collagenase Clostridium Histolyticum.《盐酸克伦特罗治疗男性 Peyronie 病患者的曲率改善预测因子》
J Sex Med. 2022 Nov;19(11):1680-1686. doi: 10.1016/j.jsxm.2022.08.001. Epub 2022 Sep 17.
3
Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes.患有 Peyronie 病的男性的特征及胶原酶注射治疗失败:手术干预和结果的预测因素。
J Sex Med. 2020 May;17(5):1005-1011. doi: 10.1016/j.jsxm.2020.02.002. Epub 2020 Feb 29.
4
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.溶组织梭状芽孢杆菌胶原酶注射治疗佩罗尼氏病患者的临床安全性和有效性:一项3期开放标签研究。
J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12.
5
Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.采用胶原酶组织溶菌素和真空疗法治疗 Peyronie 病:一项随机、开放标签的初步研究。
J Sex Med. 2017 Nov;14(11):1430-1437. doi: 10.1016/j.jsxm.2017.08.015. Epub 2017 Sep 30.
6
Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study.预测胶原酶注射治疗 Peyronie 病后患者及其伴侣性功能改善的因素:一项多中心单臂研究的结果。
J Sex Med. 2018 May;15(5):716-721. doi: 10.1016/j.jsxm.2018.03.084.
7
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.胶原酶注射治疗急性期 Peyronie 病的安全性和疗效。
J Sex Med. 2017 Oct;14(10):1220-1225. doi: 10.1016/j.jsxm.2017.08.008. Epub 2017 Sep 2.
8
Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.西地那非 25 毫克口腔崩解片+胶原酶梭菌组织溶解酶与单独使用胶原酶梭菌组织溶解酶治疗阴茎硬结症的比较:配对比较分析。
J Sex Med. 2018 Oct;15(10):1472-1477. doi: 10.1016/j.jsxm.2018.08.012. Epub 2018 Sep 20.
9
Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.溶组织梭状芽孢杆菌胶原酶治疗后持续性佩罗尼氏病的手术矫正
J Sex Med. 2015 Jan;12(1):259-64. doi: 10.1111/jsm.12721. Epub 2014 Oct 27.
10
Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.联合胶原酶梭菌和 RestoreX 阴茎牵引治疗在 Peyronie 病男性中的疗效。
J Sex Med. 2019 Jun;16(6):891-900. doi: 10.1016/j.jsxm.2019.03.007. Epub 2019 Apr 5.

引用本文的文献

1
Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities.佩罗尼氏病:基于结果的非手术及新型治疗方式指南
Res Rep Urol. 2023 Feb 2;15:55-67. doi: 10.2147/RRU.S278796. eCollection 2023.
2
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.胶原酶溶组织梭菌:在阴茎硬结症中的评价。
Clin Drug Investig. 2020 Jan;40(1):83-92. doi: 10.1007/s40261-019-00867-5.
3
Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature.预测对胶原酶注射治疗 Peyronie 病反应的特征:文献复习。
World J Urol. 2020 Feb;38(2):279-285. doi: 10.1007/s00345-019-02850-3. Epub 2019 Jun 26.
4
Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.历经六十年的历程:胶原酶溶组织梭菌,从实验台走向 FDA 批准并不断发展。
World J Urol. 2020 Feb;38(2):269-277. doi: 10.1007/s00345-019-02818-3. Epub 2019 Jun 5.

本文引用的文献

1
Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Drugs Today (Barc). 2015 Aug;51(8):457-68. doi: 10.1358/dot.2015.51.8.2375756.
2
Peyronie's Disease: AUA Guideline.佩罗尼氏病:美国泌尿外科学会指南。
J Urol. 2015 Sep;194(3):745-53. doi: 10.1016/j.juro.2015.05.098. Epub 2015 Jun 9.
3
Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.在 2 项大型、双盲、随机、安慰剂对照的 3 期研究中评估胶原酶注射治疗 Peyronie 病的临床疗效、安全性和耐受性。
J Urol. 2013 Jul;190(1):199-207. doi: 10.1016/j.juro.2013.01.087. Epub 2013 Jan 31.
4
Psychological impact of Peyronie's disease: a review.佩罗尼氏病的心理影响:综述。
J Sex Med. 2013 Mar;10(3):653-60. doi: 10.1111/j.1743-6109.2012.02999.x. Epub 2012 Nov 15.
5
Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound.勃起功能障碍的血管评估标准化:双功能超声操作标准。
J Sex Med. 2013 Jan;10(1):120-9. doi: 10.1111/j.1743-6109.2012.02825.x. Epub 2012 Sep 12.
6
Risk factors for emotional and relationship problems in Peyronie's disease.佩罗尼氏病中情绪和人际关系问题的风险因素。
J Sex Med. 2008 Sep;5(9):2179-84. doi: 10.1111/j.1743-6109.2008.00949.x. Epub 2008 Jul 14.
7
The chronology of depression and distress in men with Peyronie's disease.佩罗尼氏病男性患者抑郁和痛苦的时间顺序。
J Sex Med. 2008 Aug;5(8):1985-90. doi: 10.1111/j.1743-6109.2008.00895.x. Epub 2008 Jun 28.
8
Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction.阴茎创伤:佩罗尼氏病和勃起功能障碍的一个病因
J Urol. 1997 Oct;158(4):1388-90. doi: 10.1016/s0022-5347(01)64222-8.
9
Penile vascular evaluation of men with Peyronie's disease.佩罗尼氏病男性患者的阴茎血管评估。
J Urol. 1993 Jan;149(1):53-5. doi: 10.1016/s0022-5347(17)35997-9.
10
Peyronie's disease and erectile failure.
J Urol. 1983 Dec;130(6):1103-4. doi: 10.1016/s0022-5347(17)51706-1.